Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial.

Herbst RS, Baas P, Perez-Gracia JL, Felip E, Kim DW, Han JY, Molina JR, Kim JH, Dubos Arvis C, Ahn MJ, Majem M, Fidler MJ, Surmont V, de Castro G, Garrido M, Shentu Y, Emancipator K, Samkari A, Jensen EH, Lubiniecki GM, Garon EB.

Ann Oncol. 2019 Feb 1;30(2):281-289. doi: 10.1093/annonc/mdy545.

PMID:
30657853
2.

T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.

Ott PA, Bang YJ, Piha-Paul SA, Razak ARA, Bennouna J, Soria JC, Rugo HS, Cohen RB, O'Neil BH, Mehnert JM, Lopez J, Doi T, van Brummelen EMJ, Cristescu R, Yang P, Emancipator K, Stein K, Ayers M, Joe AK, Lunceford JK.

J Clin Oncol. 2019 Feb 1;37(4):318-327. doi: 10.1200/JCO.2018.78.2276. Epub 2018 Dec 13.

PMID:
30557521
3.

Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.

Carlino MS, Long GV, Schadendorf D, Robert C, Ribas A, Richtig E, Nyakas M, Caglevic C, Tarhini A, Blank C, Hoeller C, Bar-Sela G, Barrow C, Wolter P, Zhou H, Emancipator K, Jensen EH, Ebbinghaus S, Ibrahim N, Daud A.

Eur J Cancer. 2018 Sep;101:236-243. doi: 10.1016/j.ejca.2018.06.034. Epub 2018 Aug 7.

4.

Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer.

Kulangara K, Zhang N, Corigliano E, Guerrero L, Waldroup S, Jaiswal D, Ms MJ, Shah S, Hanks D, Wang J, Lunceford J, Savage MJ, Juco J, Emancipator K.

Arch Pathol Lab Med. 2019 Mar;143(3):330-337. doi: 10.5858/arpa.2018-0043-OA. Epub 2018 Jul 20.

PMID:
30028179
5.

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB.

Adv Anat Pathol. 2017 Nov;24(6):311-335. doi: 10.1097/PAP.0000000000000161. Review.

6.

Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.

Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB.

Adv Anat Pathol. 2017 Sep;24(5):235-251. doi: 10.1097/PAP.0000000000000162. Review.

7.

Programmed Death Ligand 1 Expression in Paired Non-Small Cell Lung Cancer Tumor Samples.

Cho JH, Sorensen SF, Choi YL, Feng Y, Kim TE, Choi H, Georgsen JB, Dolled-Filhart M, Emancipator K, Meldgaard P, Sun JM, Kim HK, Choi YS, Shim YM, Zhou W, Hager H, Kim J.

Clin Lung Cancer. 2017 Nov;18(6):e473-e479. doi: 10.1016/j.cllc.2017.04.008. Epub 2017 Apr 24.

PMID:
28669849
8.

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal.

Ott PA, Piha-Paul SA, Munster P, Pishvaian MJ, van Brummelen EMJ, Cohen RB, Gomez-Roca C, Ejadi S, Stein M, Chan E, Simonelli M, Morosky A, Saraf S, Emancipator K, Koshiji M, Bennouna J.

Ann Oncol. 2017 May 1;28(5):1036-1041. doi: 10.1093/annonc/mdx029.

9.

Retrospective Molecular Epidemiology Study of PD-L1 Expression in Patients with EGFR-Mutant Non-small Cell Lung Cancer.

Cho JH, Zhou W, Choi YL, Sun JM, Choi H, Kim TE, Dolled-Filhart M, Emancipator K, Rutkowski MA, Kim J.

Cancer Res Treat. 2018 Jan;50(1):95-102. doi: 10.4143/crt.2016.591. Epub 2017 Mar 17.

10.

Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial.

Hui R, Garon EB, Goldman JW, Leighl NB, Hellmann MD, Patnaik A, Gandhi L, Eder JP, Ahn MJ, Horn L, Felip E, Carcereny E, Rangwala R, Lubiniecki GM, Zhang J, Emancipator K, Roach C, Rizvi NA.

Ann Oncol. 2017 Apr 1;28(4):874-881. doi: 10.1093/annonc/mdx008.

11.

PD-L1 expression and survival among melanoma patients treated with standard immunotherapy or chemotherapy.

Steiniche T, Vestergaard Danielsen A, Wang Z, Feng Y, Switten Nielsen P, Bastholt L, Schmidt H, Svane IM, Dolled-Filhart M, Emancipator K, Weiner R, Busch-Sørensen M, Zhou W.

J Eur Acad Dermatol Venereol. 2017 Jul;31(7):e319-e321. doi: 10.1111/jdv.14106. Epub 2017 Jan 31. No abstract available.

PMID:
28045203
12.

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.

Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K, Richardson W, Towne P, Hanks D, Vennapusa B, Mistry A, Kalamegham R, Averbuch S, Novotny J, Rubin E, Emancipator K, McCaffery I, Williams JA, Walker J, Longshore J, Tsao MS, Kerr KM.

J Thorac Oncol. 2017 Feb;12(2):208-222. doi: 10.1016/j.jtho.2016.11.2228. Epub 2016 Nov 29.

13.

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.

Daud AI, Wolchok JD, Robert C, Hwu WJ, Weber JS, Ribas A, Hodi FS, Joshua AM, Kefford R, Hersey P, Joseph R, Gangadhar TC, Dronca R, Patnaik A, Zarour H, Roach C, Toland G, Lunceford JK, Li XN, Emancipator K, Dolled-Filhart M, Kang SP, Ebbinghaus S, Hamid O.

J Clin Oncol. 2016 Dec;34(34):4102-4109. Epub 2016 Oct 31.

14.

Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue.

Dolled-Filhart M, Locke D, Murphy T, Lynch F, Yearley JH, Frisman D, Pierce R, Weiner R, Wu D, Emancipator K.

Arch Pathol Lab Med. 2016 Nov;140(11):1259-1266.

PMID:
27788043
15.

Development of a Companion Diagnostic for Pembrolizumab in Non-Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1.

Dolled-Filhart M, Roach C, Toland G, Stanforth D, Jansson M, Lubiniecki GM, Ponto G, Emancipator K.

Arch Pathol Lab Med. 2016 Aug 23. [Epub ahead of print]

PMID:
27552095
16.

Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer.

Roach C, Zhang N, Corigliano E, Jansson M, Toland G, Ponto G, Dolled-Filhart M, Emancipator K, Stanforth D, Kulangara K.

Appl Immunohistochem Mol Morphol. 2016 Jul;24(6):392-7. doi: 10.1097/PAI.0000000000000408.

17.

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial.

Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B, McRee AJ, Lin CC, Pathiraja K, Lunceford J, Emancipator K, Juco J, Koshiji M, Bang YJ.

Lancet Oncol. 2016 Jun;17(6):717-726. doi: 10.1016/S1470-2045(16)00175-3. Epub 2016 May 3.

PMID:
27157491
18.

Prognostic Significance of PD-L1 in Patients with Non-Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases.

Sun JM, Zhou W, Choi YL, Choi SJ, Kim SE, Wang Z, Dolled-Filhart M, Emancipator K, Wu D, Weiner R, Frisman D, Kim HK, Choi YS, Shim YM, Kim J.

J Thorac Oncol. 2016 Jul;11(7):1003-11. doi: 10.1016/j.jtho.2016.04.007. Epub 2016 Apr 18.

19.

PD-L1 Expression and Survival among Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy.

Sorensen SF, Zhou W, Dolled-Filhart M, Georgsen JB, Wang Z, Emancipator K, Wu D, Busch-Sørensen M, Meldgaard P, Hager H.

Transl Oncol. 2016 Feb;9(1):64-69. doi: 10.1016/j.tranon.2016.01.003.

20.

Pembrolizumab for the treatment of non-small-cell lung cancer.

Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L; KEYNOTE-001 Investigators.

N Engl J Med. 2015 May 21;372(21):2018-28. doi: 10.1056/NEJMoa1501824. Epub 2015 Apr 19.

21.

Performance characteristics of 6 third-generation assays for thyroid-stimulating hormone.

Waskiewicz D, Burkhardt A, Emancipator K.

Clin Chem. 2005 Oct;51(10):1904-5; author reply 1905. No abstract available.

22.

Failure of assay to identify low cobalamin concentrations. Representatives of Bayer Diagnostics respond.

Emancipator K, Mansbach L, Robert T, Waskiewicz D.

Clin Chem. 2000 Dec;46(12):2018-9. No abstract available.

23.

Laboratory diagnosis and monitoring of diabetes mellitus.

Emancipator K.

Am J Clin Pathol. 1999 Nov;112(5):665-74. Review.

PMID:
10549254
24.

An algorithm for finding the linear region in a nonlinear data set.

Kroll MH, Emancipator K, Floering D, Tholen D.

Comput Biol Med. 1999 Sep;29(5):289-301.

PMID:
10463796
25.

Critical values: ASCP practice parameter. American Society of Clinical Pathologists.

Emancipator K.

Am J Clin Pathol. 1997 Sep;108(3):247-53.

PMID:
9291451
26.

Methods to quantify deviations from assay linearity.

Emancipator K.

Clin Chem. 1994 Sep;40(9):1783-6. No abstract available.

27.

A quantitative measure of nonlinearity.

Emancipator K, Kroll MH.

Clin Chem. 1993 May;39(5):766-72. Erratum in: Clin Chem 1993 Aug;39(8):1589.

28.

A theoretical evaluation of linearity.

Kroll MH, Emancipator K.

Clin Chem. 1993 Mar;39(3):405-13.

30.

Immunohistologic demonstration of myocardial proteins with applications.

Emancipator K, Urankar-Nagy N, Leonard KA, Bradford G, Emancipator SN.

Am J Clin Pathol. 1992 Mar;97(3):376-80.

PMID:
1371901
31.

In vitro inactivation of bacterial endotoxin by human lipoproteins and apolipoproteins.

Emancipator K, Csako G, Elin RJ.

Infect Immun. 1992 Feb;60(2):596-601.

32.

Comparison of two automated nephelometers.

Emancipator K, Elin RJ, Fleisher TA.

J Clin Lab Anal. 1992;6(6):399-404.

PMID:
1432366
33.

Urine and serum pregnancy tests compared.

Emancipator K.

Clin Chem. 1991 Feb;37(2):302-3. No abstract available.

34.
35.

Bromide interference: is less really better?

Emancipator K, Kroll MH.

Clin Chem. 1990 Aug;36(8 Pt 1):1470-3.

36.

Sensitivity, specificity, and reproducibility of four measures of laboratory turnaround time.

Valenstein PN, Emancipator K.

Am J Clin Pathol. 1989 Apr;91(4):452-7.

PMID:
2929500
37.

Secretion of creatine kinase MB isoenzyme by an immature teratoma with predominant rhabdomyosarcomatous elements.

Emancipator K, Kudelka AP, Bradford G, Leonard KA, Zarrabi MH.

Clin Chem. 1988 Dec;34(12):2600-2.

38.

Analytical versus clinical sensitivity and specificity in pregnancy testing.

Emancipator K, Cadoff EM, Burke MD.

Am J Obstet Gynecol. 1988 Mar;158(3 Pt 1):613-6.

PMID:
3348324
39.

Evaluation of IMACK-MB, an immunologic extraction assay for the MB isoenzyme of creatine kinase.

Emancipator K, Bradford G, Burke MD.

Clin Chem. 1988 Feb;34(2):434. No abstract available.

40.

Hidden and classical 19S IgM rheumatoid factor in a juvenile rheumatoid arthritis patient.

Emancipator K, Moore TL, Dorner RW, Sheridan PW, Eisenwinter RK, Zuckner J.

J Rheumatol. 1985 Apr;12(2):372-5.

PMID:
3897537

Supplemental Content

Loading ...
Support Center